A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

A 2002 mouse experiment reported fewer antagonist-precipitated withdrawal signs with a Passiflora-derived benzoflavone fraction. The finding concerns a defined experimental preparation and animal model, not a demonstrated treatment for cannabis-use disorder in people.

Concurrent and acute interventions were tested

Mice received repeated oral THC with or without the fraction. A later CB1 antagonist challenge provoked withdrawal-related signs, and combination-treated groups showed fewer paw tremors and head shakes. The fraction was also tested acutely after withdrawal signs appeared.

The trigger was receptor blockade

The abstract attributes the challenge to an abrupt decline in brain THC, but it does not report a concentration measurement establishing that explanation. The directly described intervention was administration of a cannabinoid receptor antagonist. Receptor blockade and demonstrated elimination of THC are not interchangeable mechanisms.

Preparation identity limits consumer extrapolation

A benzoflavone fraction is not necessarily equivalent to a commercial passionflower tea, supplement or extract. The abstract does not establish human efficacy, product consistency, safety or effects on drug-seeking behavior. Historical claims about lack of treatments are not presented here as current facts.

Applying the distinction

For a withdrawal claim, retain how withdrawal was produced and which signs changed. An antagonist-triggered animal challenge does not directly measure the frequency, duration or treatment response of naturally occurring human withdrawal. Fewer selected signs also do not establish a change in the broader behavioral features of a use disorder.

What the finding means

The study supplies preclinical evidence on selected withdrawal signs and intervention timing. It does not support self-treatment or establish prevention of addiction. Dependence-model signs, broader compulsive use and clinical recovery require different evidence.

For related interpretation, see interpreting cannabis tolerance claims.

Research reference

Dhawan K; Kumar S; Sharma A (2002). Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction. The Journal of pharmacy and pharmacology. doi:10.1211/0022357021779069.

This discussion draws on the supplied study abstract.